Silence Therapeutics plc

SLN Nasdaq CIK: 0001479615

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation United Kingdom
Country United Kingdom
Business Address 12 HAMMERSMITH GROVE, LONDON, , W6 7AP
Mailing Address 12 HAMMERSMITH GROVE, LONDON, , W6 7AP
Phone 44-0-20-3457 6900
EIN 000000000

Financial Overview

FY2024

$27.22M
Stockholders' Equity
$121.33M
Cash & Equivalents
$-0.33
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report February 13, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 9, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC
4 Insider stock transaction report December 22, 2025 View on SEC
8-K Current report of material events December 22, 2025 View on SEC
8-K/A Current report amendment December 22, 2025 View on SEC

Material Events

8-K Leadership Change December 15, 2025
High Impact
  • Silence Therapeutics plc's President and CEO, Craig Tooman, has departed by mutual agreement and stepped down from the Board of Directors.
  • Iain Ross, the current Chairman of the Board, has been appointed as interim CEO.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.